Intensifying competition following the expiry of regulatory protection for Eisurei (pirfenidone) in China
The risk that, following the expiry of the regulatory protection period for Eisurei (pirfenidone) in China, competition from other treatments and generic drugs will intensify, reducing sales opportunities and profitability.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.